Crotamiton

證據等級: L5

預測適應症: 0 個

CROTAMITON: Antiparasitic Drug — TxGNN Prediction Data Unavailable

One-Sentence Summary

Crotamiton is a topical antiparasitic and antipruritic agent, traditionally used for the treatment of scabies and relief of pruritus (itching). However, the current Evidence Pack contains no TxGNN-predicted new indications, which means a standard repurposing evaluation cannot be completed at this stage. This report documents the data gaps and recommends remediation steps before further evaluation.

Quick Overview

Item	Content
Original Indication	Scabies treatment; antipruritic (topical)
Predicted New Indication	— (No TxGNN predictions available)
TxGNN Prediction Score	—
Evidence Level	L5 (Model prediction unavailable — no supporting studies in this pack)
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Safety Considerations

No safety data was available in this Evidence Pack. All key warnings, contraindications, and drug interaction data were flagged as data gaps.

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack for Crotamiton (DB00265) is incomplete — no TxGNN-predicted indications were returned, no MOA data is available, the drug is not registered in New Zealand, and all safety fields are empty. There is currently insufficient evidence to evaluate any repurposing candidate.

To proceed, the following is needed:

Run TxGNN pipeline for Crotamiton to obtain disease-score predictions (predicted_indications array is currently empty)
Retrieve MOA data from DrugBank — DrugBank query was successful (result_count: 1) but MOA was not extracted into this pack; re-run extraction
Retrieve safety data — download and parse the package insert PDF from the regulatory authority to populate key_warnings and contraindications
Check DDI database with alternative search terms (e.g., brand name Eurax) as the current query returned no results
Re-generate this Evidence Pack (suggest upgrading from v4 to v5) after filling the above data gaps, then re-run evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.